Q-omics provides the consensus-scored MTCYBP40 profile across patient tissues and cancer cell-line models. MTCYBP40 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, MTCYBP40 is differentially expressed in 1, with the highest sampling consensus in ESCA. Additionally, MTCYBP40 RNA expression shows 5,608 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight PAAD, ESCA, and LSCC as cancer lineages where MTCYBP40 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCYBP40 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCYBP40 survival associations across molecular data types. MTCYBP40 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCYBP40 RNA expression–survival associations across cancer types. High MTCYBP40 expression shows unfavorable associations in PAAD, DLBC, BLCA, BRCA, KIRC and OV. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for MTCYBP40 RNA expression.
This table summarizes MTCYBP40 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for MTCYBP40. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCYBP40 shows higher tumor expression in ESCA. The ESCA box plot shows higher MTCYBP40 RNA expression in tumor versus normal tissue (log2 FC = +0.050, t-test p = .037).
This table shows molecular features associated with MTCYBP40 in patient tissues and cancer cell lines. In patient samples, MTCYBP40 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
